Dr. William Lavery, MD, PHD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 123
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
KS license 04-43248 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 1,622
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,583 | 47 |
| Professional service for preparation and provision of 1 or more antigens | 2,452 | 46 |
| Professional service for multiple injections of allergen | 789 | 46 |
| Test for allergy using allergenic extract injected into skin | 589 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 316 | 200 |
| Test to measure rate of airflow | 265 | 152 |
| Administration and interpretation of patient-focused health risk assessment | 202 | 123 |
| Established patient office or other outpatient visit, 20-29 minutes | 101 | 84 |
| New patient office or other outpatient visit, 30-44 minutes | 83 | 83 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Overland PArk, KS | 110 |
| Fluticasone Propionate Other prescribers in Overland PArk, KS | 60 |
| Azelastine Hcl Other prescribers in Overland PArk, KS | 49 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Overland PArk, KS | 38 |
| Famotidine Other prescribers in Overland PArk, KS | 35 |
| Ipratropium Bromide Other prescribers in Overland PArk, KS | 31 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Overland PArk, KS | 29 |
| Dulera (mometasone/formoterol) Other prescribers in Overland PArk, KS | 23 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Overland PArk, KS | 23 |
| Pantoprazole Sodium Other prescribers in Overland PArk, KS | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $16,539,356 in research payments for these studies, mostly to the institutions running them.
- SOBI.SEL110-003
Swedish Orphan Biovitrum Ab - PRGB-TBZ-4001
Mylan Pharmaceuticals Inc. - GABA-TBZ-4001
Mylan Pharmaceuticals Inc. - Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Deciphera Pharmaceuticals Inc. · Completed · NCT07158398 - GABA-TBZ-4002
Mylan Pharmaceuticals Inc. - An Open-Label, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline with Immediate-release Trospium Chloride in Adolescents with Psychiatric Disorders
E.r. Squibb & Sons, L.l.c. - Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Deciphera Pharmaceuticals Inc. · Completed · NCT07158411 - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.